StockData

Ligand Pharmaceuticals vs Organigram Global

LGND and OGI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGND and OGI compare

Organigram Global grew revenue faster over the last twelve months (77.8% versus 1.0% for Ligand Pharmaceuticals).

Ligand Pharmaceuticals scores higher on the StockData Score (6 against 4 for Organigram Global), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGNDOGI
Size and price
Market cap$5.9B–
Share price$293.81$0.707
Change, 1 year46.3%−53.2%
Change, 5 years87.3%−91.8%
Beta (5Y)0.841.27
Employees47–
StockData Score
Total score6 (better)4
Valuation score00
Growth score13 (better)
Performance score3 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/E128×–
P/S23.2×–
P/B6.1×–
EV/EBITDA108×–
P/FCF64.8×–
FCF yield1.5%–
Fair value$55.15–
Margin of safety−433%–
Growth
Revenue growth (TTM)1.0%77.8% (better)
Revenue growth, 5Y average10.4%83.6% (better)
Net income growth (TTM)5.9%–
EPS growth (TTM)18.7%–
Profitability
Gross margin–34.8%
Operating margin10.1% (better)−5.9%
Net margin20.3%–
FCF margin35.7% (better)−9.5%
Return on equity5.4%–
Return on invested capital2.6%–
Financial health
Debt / equity1.17–
Net debt / EBITDA11.26 (better)−31.24
Interest coverage3.1×–
Current ratio1.222.26 (better)
Altman Z-score3.32–
Piotroski F-score6–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions113%5.7%
Held by insiders2.6%31.4%
Insider net buying, 12 months−$36.5M–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.